Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | METAP1 | P53582 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922257 | 0.90 | METAP1 (0.55) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL13495344 | 0.83 | ALDH1A1 (0.62) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL23926949 | 0.81 | KDM4E (0.48) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL6074566 | 0.80 | HTT (0.53) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL29853451 | 0.78 | METAP1 (0.53) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL26768760 | 0.78 | METAP1 (0.53) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL8343209 | 0.78 | METAP1 (0.50) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL578369 | 0.77 | LMNA (0.60) | ALDH1A1HPGDGAACYP1A2KMT2A | |
| SCHEMBL7934255 | 0.77 | ALDH1A1 (0.51) | ALDH1A1HPGDGAAKDM4ECYP1A2 | |
| SCHEMBL9390048 | 0.77 | CASP6 (0.44) | GAAKMT2AMEN1METAP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195486-A | Impurities of amide derivatives and application thereof | 江苏恩华药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020125580-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020125580-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| CN-111320619-A | Impurities of amide-like derivatives and application | 江苏恩华药业股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | ALDH1A1 1369/4885HPGD 1774/4885GAA 2005/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | ALDH1A1 1520/4885HPGD 1617/4885GAA 760/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | ALDH1A1 1379/4885HPGD 1763/4885GAA 1991/4885 |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NOTUM, CYP51A1, HADHB | ALDH1A1 339/4885HPGD 755/4885GAA 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.